A modified anticancer drug can simultaneously target tumor sites and show whether or not it is working
Cancer drugs can be modified to specifically target tumor sites to help personalize cancer treatment. And while it is relatively easy to determine if the drugs have been delivered to the correct location, it is more difficult to monitor their therapeutic success. Now, a team led by Bin Liu from the A*A*STAR Institute of Materials Research and Engineering in Singapore, in collaboration with Ben Zhong Tang at Hong Kong University of Science and Technology, has developed an anticancer drug with an inbuilt mechanism that shows if it is working1.
Platinum-based drugs are effective against many cancers, killing cells by triggering cellular suicide, or apoptosis. These drugs can, however, have severe side effects. Nontoxic forms can be modified, as a type of prodrug, to convert to their toxic form only after entering the targeted tumor cells, so as not to harm noncancerous cells.
Liu and colleagues went one step further by modifying a platinum-based prodrug to not only target tumor cells effectively, but also show whether or not it was having the desired effect. According to Liu, this added feature could be crucial for improving cancer treatment.
“Early evaluation of a patient’s response to a specific cancer therapy is important in clinical applications because it can minimize the duration of ineffective courses,” explains Liu. “The effectiveness of cancer treatment is commonly evaluated using magnetic resonance imaging to measure the tumor size, but this is unsatisfactory as the change in size is not obvious at the early stages of therapy.”
In their new system, Liu and her team included an apoptosis sensor that is released when the prodrug converts to its toxic form inside the targeted tumor cells. The toxic form triggers cell apoptosis and activates an enzyme called caspase 3, which then cleaves the apoptosis sensor and causes it to fluoresce green. This provides a visual signal that the drug is killing the cells.
The Latest on: Anticancer drug
via Google News
The Latest on: Anticancer drug
- FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug Liston December 2, 2019 at 3:00 am
Roxadustat was among 97 drugs that were included on the updated NRDL list through negotiations ... in China for anemia associated with myelodysplastic syndromes (MDS), and in a Phase 2 U.S. trial for ...
- Recent Business Report On Chemotherapy Drugs Market By Major Key Vendors 2018-2023on December 1, 2019 at 9:31 pm
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of ...
- Can precision medicine make chemotherapy a thing of the past?on November 30, 2019 at 9:07 pm
Chemotherapy has been a mainstay of cancer treatment for decades ... and we can attribute it largely to this new class of targeted cancer killers — drugs like erlotinib (Tarceva), osimertinib ...
- Multi-layered core-sheath fiber membranes for controlled drug release in the local treatment of brain tumoron November 29, 2019 at 3:31 am
Historically, BCNU has played a pivotal role in GBM treatment, first as a systemic chemotherapy, and more recently, over the last 20 years, as a locally administered compound from the Gliadel ® wafer.
- Discovering the Microbial Enzymes Driving Drug Toxicity with Activity-Based Protein Profilingon November 29, 2019 at 2:52 am
It is increasingly clear that interindividual variability in human gut microbial composition contributes to differential drug responses. For example, gastrointestinal (GI) toxicity is not observed in ...
- Chi-Med’s Elunate® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in Chinaon November 28, 2019 at 5:06 am
LONDON, Nov. 28, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Elunate ® (fruquintinib capsules), its national class 1 targeted ...
- Chi-Med's Elunate(R) (Fruquintinib Capsules) Included in the National Reimbursement Drug List in Chinaon November 27, 2019 at 10:15 pm
LONDON, Nov 28, 2019 (GLOBE NEWSWIRE via COMTEX) -- LONDON, Nov. 28, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited ("Chi-Med") (aim/nasdaq:HCM) today announces that Elunate [(R)] ...
- Mounting drug shortages delay treatments for patients with bladder canceron November 27, 2019 at 3:29 pm
But the treatment she got seemed to work: a drug called BCG. Then another bombshell: there was a shortage of that drug. The medicine she then received instead, a chemotherapy drug called gemcitabine, ...
- UC professor, student invent new way to deliver cancer drugson November 27, 2019 at 10:36 am
Cliff Larrabee, a chemistry professor at University of Cincinnati Clermont College, and his former student Mary Warmin have filed an application to patent a new method of delivering chemotherapy drugs ...
- New method can deliver chemotherapy drugs directly to malignant cellson November 27, 2019 at 10:07 am
Now, a research team headed by Professor Alexander Binshtok, head of the Pain Plasticity Research Group at the Hebrew University of Jerusalem's Faculty of Medicine and Edmond & Lily Safra Center for ...
via Bing News